Arcadia Biosciences AI Stock Analysis
Want to see RKDA full AI Analyst Report?
Arcadia Biosciences (RKDA) AI Stock Analysis
Arcadia Biosciences
(NASDAQ:RKDA)
The score is pressured primarily by persistent losses and ongoing cash burn alongside sharply reduced equity, which elevate financing/dilution risk. Technicals also remain weak with negative momentum and the stock below key longer-term moving averages. Valuation support is limited due to negative earnings and no dividend, while corporate events add incremental risk due to Nasdaq compliance concerns despite steps to improve flexibility.
Arcadia Biosciences (RKDA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $343.50K
- Dividend Yield
- ―
- Average Volume (3M)
- 2.24M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.78
- Revenue Growth
- -12.24%
- EPS Growth
- 17.56%
- Country
- US
- Employees
- 8
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Agricultural Inputs
Arcadia Biosciences Business Overview & Revenue Model
Company Description
Arcadia Biosciences, Inc. is a U.S.-based company that provides plant-derived health and well-being products. Additionally, it is actively engaged in agricultural research and development, with a particular focus on improving wheat crops. The aim of...
Arcadia Biosciences Earnings Call Summary
The earnings call reflected a strong start to 2025, with significant revenue growth in the Zola brand and effective cost control measures. However, challenges such as a decline in gross margin and an increase in inventory and cash consumption were noted. The pending business combination with Roosevelt Resources is a positive development, enhancing future prospects.
Q1-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the Arcadia Biosciences, Inc. first-quarter 2025 conference call, significant growth and strategic shifts were highlighted. The company reported a remarkable 90% year-over-year increase in revenue for its Zola coconut water, primarily due to a 70% rise in new distribution channels. Operating expenses saw a 16% reduction, despite incurring nearly half a million dollars in transaction-related fees. The gross margin stood at 43%, maintaining a trend of exceeding 30% for nine consecutive quarters. Arcadia continued to monetize its intellectual property, securing $750,000 in cash for certain soy patents, which allowed for the elimination of a $1,000,000 contingent liability. The pending business combination with Roosevelt Resources is progressing, aiming for completion by late summer, with a fixed equity share ratio of 90-10 between Roosevelt Partners and Arcadia stockholders. The call also mentioned a strong pipeline and new product innovations expected to further boost Zola's market presence. Overall, the company is focused on streamlining operations and enhancing financial performance in 2025.
Arcadia Biosciences Financial Statement Overview
Summary
Revenue is growing and gross margin is positive (~35%), and the company has effectively no debt. However, profitability remains very weak with large operating losses and a deeply negative net margin, equity has eroded sharply over time, and operating/free cash flow are still negative (TTM OCF/FCF about -$3.6M), implying elevated funding and dilution risk until margins and cash generation improve.
Income Statement
22NegativeBalance Sheet
62PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.06M | 4.86M | 5.04M | 4.45M | 7.42M | 6.78M |
| Gross Profit | 2.08M | 1.76M | 2.08M | 2.28M | 1.32M | -1.93M |
| EBITDA | -12.81M | -2.30M | -6.85M | -5.73M | -14.75M | -27.71M |
| Net Income | -10.23M | -2.34M | -7.04M | -13.98M | -15.38M | -14.66M |
Balance Sheet | ||||||
| Total Assets | 4.72M | 6.55M | 13.52M | 19.70M | 28.92M | 43.92M |
| Cash, Cash Equivalents and Short-Term Investments | 2.84M | 4.56M | 4.24M | 11.64M | 20.64M | 28.68M |
| Total Debt | 0 | 0 | 155.00K | 1.01M | 2.02M | 3.29M |
| Total Liabilities | 2.31M | 2.41M | 7.29M | 7.00M | 8.02M | 12.72M |
| Stockholders Equity | 2.40M | 4.14M | 6.22M | 12.84M | 21.03M | 31.09M |
Cash Flow | ||||||
| Free Cash Flow | -3.56M | -4.74M | -9.64M | -15.30M | -14.05M | -26.88M |
| Operating Cash Flow | -3.56M | -4.74M | -9.63M | -15.29M | -13.98M | -25.87M |
| Investing Cash Flow | 0 | 750.00K | 7.34M | -4.34M | 1.42M | 16.61M |
| Financing Cash Flow | 5.28M | 6,000 | 9,000 | 5.51M | 4.52M | 21.90M |
Arcadia Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RKDA, the sentiment is Neutral. The current price of 0.22 is above the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.29, and below the 200-day MA of 0.93, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 59.12 is Neutral, neither overbought nor oversold. The STOCH value of 65.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RKDA.
Arcadia Biosciences Risk Analysis
Arcadia Biosciences disclosed 18 risk factors in its most recent earnings report. Arcadia Biosciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksArcadia Biosciences Peers Comparison
Overall Rating
CTVA59Neutral- RKDA44Neutral
SEED42Neutral
FMC39Underperform
BIOX38Underperform
AVD37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| CTVA | 59Neutral | $8.10B | 7.84 | 3.55% | 1.18% | 1.05% | -51.65% |
| RKDA | 44Neutral | $572.91K | -0.02 | -339.85% | ― | -12.24% | 17.56% |
| SEED | 42Neutral | $9.41M | -0.71 | 88.44% | ― | -25.50% | -905.27% |
| FMC | 39Underperform | $878.91M | -0.16 | -308.88% | 6.32% | -21.99% | -677.23% |
| BIOX | 38Underperform | $14.85M | -0.06 | -216.09% | ― | -26.10% | 14.85% |
| AVD | 37Underperform | $25.98M | -0.44 | -32.98% | ― | -5.79% | 46.69% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RKDA | Arcadia Biosciences Inc. | 0.22 | -3.55 | -94.11% | |
| AVD | American Vanguard Corporation | 0.90 | -4.18 | -82.26% | |
| FMC | FMC Corp | 5.06 | -8.48 | -62.63% | |
| SEED | Origin Agritech | 0.66 | -0.76 | -53.52% | |
| BIOX | Bioceres Crop Solutions | 0.22 | -1.46 | -86.79% | |
| CTVA | Corteva | 9.19 | -0.62 | -6.31% |
Arcadia Biosciences Corporate Events
Arcadia Biosciences Shareholders Approve Governance and Capital Moves
PositiveAt Arcadia Biosciences’ Annual Meeting held on September 10, 2026, stockholders representing about 52.3% of outstanding common shares participated in votes on a series of corporate governance and capital structure proposals. Gregory D. Waller was ele...
Arcadia Biosciences Receives Nasdaq Listing Compliance Notice
NegativeOn August 31, 2026, Arcadia Biosciences disclosed that Nasdaq had notified the company its stockholders’ equity, reported at $633,000 as of June 30, 2026, fell below the $2.5 million minimum required for continued listing on the Nasdaq Capital Market...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026